- Transfuse at Hb <7 g/dL for most hospitalized adults (AABB 2023). <8 for cardiac/orthopedic surgery or existing CVD.
- Acute MI with anemia: a more liberal strategy (Hb <10) may be reasonable (MINT trend toward benefit).
- One unit at a time, then reassess. Each unit raises Hb ~1 g/dL.
- Workup = MCV + reticulocyte count → then targeted labs. Send iron studies before transfusing if possible.
- Iron deficiency = ferritin <30 (or <100 with inflammation, CKD, HF) → find the source (GI workup in men and postmenopausal women).
Pathophysiology in 60 seconds
⌄
- Anemia = too little production (low retics) or too much loss/destruction (high retics).
- O₂ delivery = cardiac output × Hb × SaO₂. Healthy hearts compensate by raising output; ischemic hearts cannot → why CAD patients may need a higher threshold.
- Hb drops slowly in chronic anemia → patients tolerate very low values; acute bleeds look worse at the same Hb.
Diagnosis
⌄
| MCV | Low retics (production) | High retics (loss/destruction) |
|---|---|---|
| Low (<80) | Iron deficiency, thalassemia, anemia of inflammation (some), sideroblastic, lead | — |
| Normal | Anemia of inflammation/CKD, early iron deficiency, marrow failure, mixed | Acute bleed, hemolysis |
| High (>100) | B12/folate, alcohol, liver disease, hypothyroid, MDS, drugs (MTX, hydroxyurea, AZT) | Reticulocytosis itself raises MCV |
| Hemolysis labs | Pattern |
|---|---|
| LDH ↑, indirect bilirubin ↑, haptoglobin ↓, retics ↑ | Hemolysis |
| Smear: schistocytes | MAHA → TTP/HUS/DIC/valve → urgent (PLASMIC score, ADAMTS13) |
| Smear: spherocytes + DAT positive | Warm autoimmune hemolytic anemia |
| Bite cells, Heinz bodies | G6PD (after drug, infection) |
| Iron studies | Iron deficiency | Inflammation |
|---|---|---|
| Ferritin | Low (<30) | Normal/high |
| TSAT | Low (<20%) | Low |
| TIBC | High | Low |
Management
⌄
| Situation | Threshold |
|---|---|
| Most hospitalized adults, ICU | Hb <7 |
| Cardiac surgery, orthopedic surgery, pre-existing CVD | Hb <7.5–8 |
| Acute MI | Consider Hb <10 (MINT) — individualize |
| Active bleeding, hemorrhagic shock | Clinical, not a number (massive transfusion protocol) |
| Oncology / hematologic malignancy | Hb <7 (often 7–8) |
- Watch TACO (volume overload: give slowly, diurese between units in HF) and TRALI (hypoxemia within 6 h, non-cardiogenic).
- Febrile non-hemolytic reaction → stop, rule out hemolysis.
- Oral: ferrous sulfate 325 mg (65 mg elemental) once daily or every other day (better absorption, fewer GI effects).
- IV iron if: intolerance, malabsorption (celiac, bariatric), CKD, HFrEF, ongoing loss, need for fast repletion (ferric carboxymaltose, ferric derisomaltose, iron sucrose).
- Find the source: EGD + colonoscopy (men, postmenopausal women); celiac serology; menstrual history.
- B12 deficiency: IM cyanocobalamin 1000 mcg daily ×1 week → weekly → monthly, or high-dose oral 1000–2000 mcg daily (works even without intrinsic factor).
- Check B12 before giving folate (folate can mask B12 → neuro damage).
- Methylmalonic acid ↑ = B12; homocysteine ↑ in both.
Pitfalls
⌄
- Transfusing "to 8" every morning in stable patients.
- Iron studies drawn after transfusion (useless).
- Ferritin 60 called "normal" in a CKD/HF patient.
- Missing MAHA → TTP (look at the smear!).
Board corner
⌄
| Stem | Answer |
|---|---|
| Hb 6.8, ICU sepsis, stable | Transfuse 1 unit |
| Hb 7.4, no symptoms, no CAD | No transfusion |
| Microcytic, ferritin 8, man 60 y | Iron deficiency → EGD + colonoscopy |
| Schistocytes, platelets 20 k, fever, AMS | TTP → plasma exchange, caplacizumab |
| Hypoxemia 2 h after transfusion, no volume overload | TRALI |
| Macrocytosis + neuropathy + vitiligo | Pernicious anemia (B12) |
References
⌄
- Carson JL, et al. AABB International Guidelines: Red Blood Cell Transfusion. JAMA. 2023;330:1892.
- Carson JL, et al. MINT. NEJM. 2023;389:2446.
- Ko CW, et al. AGA Guideline: GI evaluation of iron deficiency anemia. Gastroenterology. 2020;159:1085.